Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
09 janv. 2023 08h01 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
09 janv. 2023 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 déc. 2022 16h35 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for patients with neuromuscular and...
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
05 déc. 2022 07h30 HE
|
Solid Biosciences Inc.
- Transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led by industry veteran Bo Cumbo - - Company to leverage synergies and key assets, including...
Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio
01 déc. 2022 16h15 HE
|
Solid Biosciences Inc.
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases - CHARLESTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc....
Solid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference
22 nov. 2022 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results
10 nov. 2022 07h34 HE
|
Solid Biosciences Inc.
- Recently presented preclinical data support potential benefits of next-generation Duchenne gene therapy candidate SGT-003; program on track for mid-2023 Investigational New Drug (IND) submission - ...
Solid Biosciences Announces a 1-for-15 Reverse Stock Split
27 oct. 2022 08h00 HE
|
Solid Biosciences Inc.
- Effective at 5 pm ET October 27, 2022 - CHARLESTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful...
Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle
17 oct. 2022 08h00 HE
|
Solid Biosciences Inc.
- AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding...
Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function
13 oct. 2022 08h00 HE
|
Solid Biosciences Inc.
- Stride velocity 95th centile (SV95C) data demonstrate improvements at one-year post-dosing compared with declines observed in control and natural history patients - - SV95C is an objective,...